Acadia Pharmaceuticals | ACAD - 营业利润



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 4.3B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


营业利润 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Cara Therapeutics USD -5.94M 3.55M 2025-09
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 9.78B 792M 2026-03
Incyte USD 700.4M 376.22M 2026-06
J&J USD 7.48B 860M 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pfizer USD 4.99B 340M 2026-03
Prothena USD 25.79M 53M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03